Interestingly, in our recently reported clinical trial of pegaspargase plus anti-PD1 antibody sintilimab in treating NKTCL,38 there was no difference in TLG between the responders and nonsresponders. The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.